CIDP: Improving Timely Diagnosis, Assessment, and Treatment

TARGET AUDIENCE
The educational design of this activity addresses the needs of neurologists, neuromuscular specialists, immunologists, primary care providers, hospitalists, emergency physicians, advanced practitioners, nurses, and pharmacists involved in the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

STATEMENT OF NEED/PROGRAM OVERVIEW
While CIDP is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues lead to delayed diagnoses, misdiagnoses, and missed opportunities for early and timely interventions.

Join experts in the management of CIDP for a comprehensive review of the symptoms and clinical features of CIDP, along with practical and successful strategies to improve diagnosis and disease assessment. The safety, efficacy, and tolerability of available treatment options will also be explored, and strategies to address barriers to optimal management and emerging concepts in disease pathophysiology that could provide new targeted options to more effectively manage CIDP will be addressed.

Because of the significant morbidity and disease burden associated with CIDP, it is critical that clinicians and their patients be on the same page in terms of diagnosis, treatment expectations, and maintenance therapy to maximize outcomes. Direct your patients with CIDP to the associated patient activity, “Becoming Empowered with CIDP: Making My Voice Heard” at NeuroCareLive.com. Patients and their caregivers will become more familiar with both current and emerging management approaches, while recognizing their role in the treatment and monitoring process.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
• Formulate a differential-diagnosis strategy for a patient presenting with symptoms suggestive of CIDP
• Identify a treatment plan using current therapeutic options, including coordination of multidisciplinary care and provision of supportive treatment
• Summarize data from ongoing clinical trials with agents targeting the IgG neonatal Fc receptor